Avalo Therapeutics, Inc. Quarterly Amortization of Intangible Assets in USD from Q1 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Avalo Therapeutics, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from Q1 2017 to Q4 2023.
  • Avalo Therapeutics, Inc. Amortization of Intangible Assets for the quarter ending December 31, 2023 was $0.000.
  • Avalo Therapeutics, Inc. Amortization of Intangible Assets for the twelve months ending December 31, 2023 was $0.000, a 100% decline year-over-year.
  • Avalo Therapeutics, Inc. annual Amortization of Intangible Assets for 2023 was $0.000, a 100% decline from 2022.
  • Avalo Therapeutics, Inc. annual Amortization of Intangible Assets for 2022 was $38K, a 97.5% decline from 2021.
  • Avalo Therapeutics, Inc. annual Amortization of Intangible Assets for 2021 was $1.55M, a 11.1% decline from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 $0 $0 $0 Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 $0 $0 $0 Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $0 $0 $0 Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $0 $0 -$38K -100% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $38K $0 -$267K -100% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $305K $0 -$428K -100% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $733K $0 -$428K -100% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $1.16M $38K -$386K -91% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $1.55M $267K -$235K -46.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $1.78M $428K +$24K +5.94% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $1.76M $428K +$24K +5.94% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $1.73M $424K -$7K -1.62% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $1.74M $502K +$167K +50% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 $1.57M $404K +$69.3K +20.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $1.5M $404K +$69.3K +20.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-02
Q1 2020 $1.44M $431K +$96.3K +28.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $1.34M $335K +$1.83M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 -$496K $335K -$731K -68.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $235K $335K -$898K -72.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $1.13M $335K -$683K -67.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $1.82M -$1.5M -$1.9M -472% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 $3.72M $1.07M +$1.07M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $2.65M $1.23M +$1.23M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $1.42M $1.02M +$1.02M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $404K $404K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $0 Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $0 Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $0 Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.